Core Viewpoint - Zimmer Biomet Holdings, Inc. (ZBH) is set to report its second-quarter 2025 results on August 7, with expectations of revenue growth driven by its Hips and Knees business segments [1][7]. Group 1: Financial Estimates - The Zacks Consensus Estimate for ZBH's revenues is $2.04 billion, reflecting a 5.3% increase from the previous year [2]. - The earnings estimate is projected at $1.98 per share, indicating a 1.5% decline from the year-ago figure [2]. - The earnings estimate has decreased by 0.5% over the past 30 days [2]. Group 2: Business Segment Performance - The Hips business is expected to grow due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated hip surgical impactor system HAMMR, with an estimated 4% year-over-year growth [3][4]. - The Knees business is anticipated to benefit from the Persona portfolio and the FDA clearance for Persona Revision SoluTion Femur, projecting a 6.2% year-over-year growth [5][6]. - The S.E.T business is expected to continue its growth trend, with a projected increase of 2.6% year-over-year, bolstered by the acquisition of Paragon 28, Inc. [7][8]. Group 3: Market Dynamics - The robotics and navigation platforms, particularly OrthoGrid, are expected to have gained market share, contributing positively to the Hips business [4]. - Sales in the Technology & Data, Bone Cement, and Surgical business are projected to report a 4.7% year-over-year growth, despite previous declines due to tough comparisons [9].